doxazosin has been researched along with erlotinib hydrochloride in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bakır, E; Cumaoğlu, A; Eken, A; Hamurcu, Z; Karaca, B; Yerer, MB | 1 |
1 other study(ies) available for doxazosin and erlotinib hydrochloride
| Article | Year |
|---|---|
Doxazosin and erlotinib have anticancer effects in the endometrial cancer cell and important roles in ERα and Wnt/β-catenin signaling pathways.
Topics: Antineoplastic Agents; beta Catenin; Doxazosin; Endometrial Neoplasms; Erlotinib Hydrochloride; Estrogen Receptor alpha; Female; Humans; Wnt Signaling Pathway | 2021 |